Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $61.63 USD
Change Today -0.25 / -0.40%
Volume 4.8M
MYL On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

mylan nv (MYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $65.63
52 Week Low
04/15/14 - $44.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYLAN NV (MYL)

mylan nv (MYL) Details

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. It offers generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. Further, the company manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. was founded in 1961 and is headquartered in Potters Bar, Hertfordshire.

25,000 Employees
Last Reported Date: 03/2/15
Founded in 1961

mylan nv (MYL) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $1.1M
President, Executive Director and Member of S...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan nv (MYL) Key Developments

Mylan Launches Buprenorphine Hydrochloride sublingual tablets, 2mg and 8mg, indicated for the treatment of opioid dependence US

Mylan launched Buprenorphine Hydrochloride sublingual tablets, 2mg and 8mg, indicated for the treatment of opioid dependence, in the US. Buprenorphine Hydrochloride Sublingual Tablets, 2 mg and 8 mg is the generic version of Reckitt Benckiser's Subutex Sublingual Tablets. Mylan received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of opioid dependence and is preferred for induction.

Mylan Wins Multiple Awardees Contract for Supplying Generic Transition Pharmaceuticals

Mylan won a multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic transition pharmaceuticals. The lowest offer is GBP 14.5 million and the highest offer is GBP 14.7 million.

Mylan NV and Mylan Inc Introduce US FDA Approved Fentanyl Transdermal System 37.5, 62.5 and 87.5 Mcg/Hr

Mylan NV and Mylan Inc. announced that it has introduced its US FDA approved Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in the nation. This launch adds to the company's existing offering of Fentanyl Transdermal System 12, 25, 50, 75 and 100 mcg/hr.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $61.63 USD -0.25

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,950 JPY -27.50
Becton Dickinson and Co $144.59 USD +1.38
Perrigo Co PLC $165.97 USD +1.65
Shire PLC 5,425 GBp +115.00
WW Grainger Inc $234.60 USD +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 26.5x
Price/Sales 3.0x
Price/Book 7.1x
Price/Cash Flow 32.5x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at